LONDON (AFX) - Cell therapy company Intercytex Group PLC reported a wider full-year pretax loss on higher research and development costs. The company, which listed on the AIM last February, said pretax losses for the year to Dec 31 widened to 9.2 mln stg from a loss of 7.2 mln stg a year earlier.
